Regulatory and intellectual property conundrums surrounding xenotransplantation
- 7 July 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 39 (7), 796-798
- https://doi.org/10.1038/s41587-021-00976-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Lessons from HeLa Cells: The Ethics and Policy of BiospecimensAnnual Review of Genomics and Human Genetics, 2016
- Current Public Support for Human-Animal Chimera Research in Japan Is Limited, Despite High Levels of Scientific ApprovalCell Stem Cell, 2016
- Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograftNature Communications, 2016
- The production of multi-transgenic pigs: update and perspectives for xenotransplantationTransgenic Research, 2016
- Strategies for stem cell patent applications in the light of recent court casesPharmaceutical Patent Analyst, 2015
- Regulatory Landscape of Regenerative Medicine in JapanCurrent Stem Cell Reports, 2015
- Regulatory uncertainty over genome editingNature Plants, 2015
- Revisiting the Flight of Icarus: Making Human Organs from PSCs with Large Animal ChimerasCell Stem Cell, 2014
- Towards developing guidelines on xenotransplantation in ChinaXenotransplantation, 2007
- Human-nonhuman chimeras: a regulatory proposal on the blurring of species lines.2004